Da Som Jeon

Dr. Da Som Jeon

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2023 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
DJDa Som Jeon
Da Som Jeon
HKHo Cheol Kim
Ho Cheol Kim
SKSe Hee Kim
Se Hee Kim
TKTae-Jung Kim
Tae-Jung Kim
HKHong Kwan Kim
Hong Kwan Kim
KRKorea Central Cancer Registry
Korea Central Cancer Registry
Purpose This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.Materials and Methods The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.Results We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).Conclusion In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.

13 April 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
DJDa Som Jeon
Da Som Jeon
SKSeonok Kim
Seonok Kim
MKMi Ae Kim
Mi Ae Kim
YCYong Pil Chong
Yong Pil Chong
TSTae Sun Shim
Tae Sun Shim
KJKyung-Wook Jo
Kyung-Wook Jo
We assessed whether patients with T2DM are at higher risk for incident NTM disease through analysis of NTM-naive matched cohorts from the data of a national population-based cohort which represents 2.2% of the total South Korean population. Although T2DM alone is not a statistically significant risk factor for NTM disease, T2DM significantly increases the risk of NTM disease in those with ≥2 diabetes-related complications.

23 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
DJDa Som Jeon
Da Som Jeon
CYChang Dong Yeo
Chang Dong Yeo
CKchi young Kim
chi young Kim
JEJung Seop Eom
Jung Seop Eom
Wonjun JiWonjun Ji
Wonjun Ji
CCChang-Min Choi
Chang-Min Choi
Background/Objectives: Blood-based biomarkers may improve risk stratification of indeterminate pulmonary nodules detected on low-dose computed tomography (LDCT). We evaluated the diagnostic performance and independent predictive value of an aptamer-based blood assay, AptoDetect™-Lung, in a high-risk Korean screening population. Methods: This multicenter prospective cohort study enrolled adults with Lung Imaging Reporting and Data System (Lung-RADS) category 3 or 4 pulmonary nodules identified on LDCT across ten tertiary hospitals in South Korea between June 2023 and December 2024. Analyses focused on a predefined high-risk subgroup meeting Korean screening criteria (age 54–74 years and ≥30 pack-years of smoking). Baseline serum AptoDetect™-Lung scores were measured. Associations with lung cancer diagnosis were assessed using univariate and multivariable logistic regression, adjusting for clinical and radiologic variables. Diagnostic performance was evaluated using receiver operating characteristic analysis. Results: Among 1084 participants with histopathologic confirmation, 319 met high-risk criteria, of whom 260 (81.5%) were diagnosed with lung cancer. In this subgroup, the AptoDetect™-Lung score was independently associated with malignancy after adjustment (adjusted odds ratio of 1.14 per unit; 95% confidence interval of 1.02–1.27; p = 0.020). Discriminative performance was higher in the high-risk subgroup than in the overall cohort (area under the curve [AUC] of 0.639 vs. 0.570; p = 0.025). Performance was higher for squamous cell carcinoma and small-cell lung cancer than for adenocarcinoma. A multivariable model incorporating biomarker score, Lung-RADS category, age, and family history achieved an AUC of 0.710. Conclusions: An aptamer-based blood biomarker may provide modest adjunctive value for risk stratification in high-risk individuals.

5 September 2026
Verified
Conference Paper
Closed access
DJDa Som Jeon
Da Som Jeon
CYChang Dong Yeo
Chang Dong Yeo
CKChi Young Kim
Chi Young Kim
JEJung Seop Eom
Jung Seop Eom
WJWonjun Ji
Wonjun Ji
CCChang-Min Choi
Chang-Min Choi
Purpose: Blood-based biomarkers may improve risk stratification of indeterminate pulmonary nodules. We evaluated the diagnostic performance and independent predictive value of an aptamer-based blood assay in a high-risk Korean screening population. Methods: This multicenter prospective cohort study enrolled adults with Lung-RADS category 3 or 4 nodules detected on LDCT at ten tertiary hospitals in South Korea (June 2023–December 2024). Analyses focused on a predefined high-risk subgroup meeting Korean screening criteria (age 54–74 years, ≥30 pack-years). Baseline AptoDetect™-Lung scores were analyzed using multivariable logistic regression, and diagnostic performance was assessed by ROC analysis. Results: Among 1,084 participants with histopathologic confirmation, 319 met high-risk criteria, of whom 260 (81.5%) had lung cancer. In this subgroup, the AptoDetect™-Lung score was independently associated with malignancy (adjusted OR 1.14; 95% CI 1.02–1.27; p=0.020). Discrimination was higher in the high-risk subgroup than in the overall cohort (AUC 0.639 vs. 0.570; p=0.025). Performance was higher for squamous cell carcinoma and small cell lung cancer than for adenocarcinoma. A combined model including biomarker score, Lung-RADS category, age, and family history achieved an AUC of 0.710. Conclusions: An aptamer-based blood biomarker independently predicted lung cancer in high-risk individuals with LDCT-detected indeterminate nodules, supporting its adjunctive role in screening-based risk stratification. erj;68/suppl_70/PA1900/F1 F1 F1